London Jonathan, Bulancea Sabrina, Shirazi Inaas, Oriuwa Victoria, Bolotova Olena, Tharayil Zubin
Department of Internal Medicine, Long Island Community Hospital, USA.
Department of Nephrology, Long Island Community Hospital, USA.
J Community Hosp Intern Med Perspect. 2024 Jul 2;14(4):65-67. doi: 10.55729/2000-9666.1362. eCollection 2024.
Pembrolizumab is utilized in the treatment of multiple different malignancies, including non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, renal cell carcinoma, endometrial cancer, and more. Pembrolizumab is an immune checkpoint inhibitor that inhibits the programmed cell death-1 (PD-1) signaling pathway. Despite its benefits in treating multiple cancers, there are many reported adverse effects of Pembrolizumab affecting various organ systems; rarely it can cause acute interstitial nephritis (AIN). We present the case of a 79-year-old male with metastatic retroperitoneal squamous cell carcinoma who was found to have recurrent acute interstitial nephritis after pembrolizumab therapy.
帕博利珠单抗被用于治疗多种不同的恶性肿瘤，包括非小细胞肺癌、头颈部鳞状细胞癌、黑色素瘤、肾细胞癌、子宫内膜癌等等。帕博利珠单抗是一种免疫检查点抑制剂，可抑制程序性细胞死亡-1（PD-1）信号通路。尽管它在治疗多种癌症方面有诸多益处，但有许多关于帕博利珠单抗的不良反应报道，其会影响各个器官系统；它很少会引起急性间质性肾炎（AIN）。我们报告了一例79岁男性转移性腹膜后鳞状细胞癌患者，该患者在接受帕博利珠单抗治疗后出现复发性急性间质性肾炎。
